Home Featured Page 119

Featured

Latest

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH...

Algernon Pharmaceuticals Announces Closing of Rights Offering

Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical...

Psychedelics Weekly – Psychedelics and Sports, The Risks of Over-Regulation, and...

COMPASS Pathways plc to announce first quarter 2023 financial results on...

The Top 5 Psychedelic Clinical Trials of 2022

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Psychedelics, The Brain, and the Future of Mental Health

atai Life Sciences to Participate in Upcoming May Investor Conference

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH...

Algernon Pharmaceuticals Announces Closing of Rights Offering

Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical...

Psychedelics Weekly – Psychedelics and Sports, The Risks of Over-Regulation, and...

COMPASS Pathways plc to announce first quarter 2023 financial results on...

The Top 5 Psychedelic Clinical Trials of 2022

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Psychedelics, The Brain, and the Future of Mental Health

atai Life Sciences to Participate in Upcoming May Investor Conference

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY